Survodutide vs Orforglipron
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: BI 456906
A dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.
Also: LY3502970, OWL833
An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo — the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Key Comparison Insights
- Orforglipron is FDA approved, while Survodutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Survodutide | Orforglipron |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Survodutide activates both GLP-1 receptors (appetite suppression, glucose control) and glucagon receptors (increased energy expenditure, reduced liver fat). The glucagon component adds metabolic benefits beyond pure GLP-1 agonists. | Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide. |
| Common Dosing | Limited community data available See research protocols | Limited community data available See research protocols |
| Administration | Subcutaneous injection weekly | Oral tablet daily |
| Typical Duration | Long-term use expected | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 2 showed 83% of patients had MASH resolution vs 18% placebo. Phase 3 SYNCHRONIZE trials for obesity expected to complete early 2026. LIVERAGE trials for MASH enrolling 3,000+ participants. | ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025. Selected for FDA National Priority Voucher program but review was delayed to April 2026. FDA approved Foundayo (orforglipron) on April 1, 2026 under the National Priority Voucher Program — the fastest new molecular entity approval since 2002. It is the first oral non-peptide GLP-1 receptor agonist approved for chronic weight management. |
Frequently Asked Questions: Survodutide vs Orforglipron
What is the difference between Survodutide and Orforglipron?
Survodutide is a weight loss peptide that a dual glp-1/glucagon receptor agonist in development for obesity and mash. has fda breakthrough therapy designation for mash with fibrosis. Orforglipron is a weight loss peptide that an oral non-peptide glp-1 receptor agonist. fda approved april 1, 2026 under the brand name foundayo — the first daily oral glp-1 pill for weight loss. distribution began april 6, 2026. fda subsequently requested additional post-approval safety data. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Survodutide or Orforglipron?
Neither is universally "better" - the choice depends on your specific goals. Survodutide is typically used for weight loss purposes, while Orforglipron is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Survodutide and Orforglipron be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Survodutide and Orforglipron together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.